VCI Global Prices $2.75M Public Offering At $1.25 Per Ordinary Share And Associated Series Warrants

 VCI Global Limited (NASDAQ:VCIG) ("VCI Global", or the "Company") today announced the pricing of a public offering of 2,200,000 the Company's ordinary shares and accompanying Series A

 VCI Global Limited (NASDAQ:VCIG) (“VCI Global”, or the “Company”) today announced the pricing of a public offering of 2,200,000 the Company’s ordinary shares and accompanying Series A warrants to purchase up to 2,200,000 ordinary shares (“Series A Warrants”) and Series B warrants to purchase up to 2,200,000 ordinary shares (“Series B Warrants”, together with Series A Warrants, collectively the “Series Warrants”) at a combined offering price of $1.25 per ordinary share and associated Series Warrants. The Series Warrants have an exercise price of $1.25 per share and will be immediately exercisable upon issuance. The Series A Warrants will expire five years following the initial exercise date, and the Series B Warrants will expire eighteen months following the initial exercise date. The closing of the offering is expected to occur on or about January 17, 2024, subject to the satisfaction of customary closing conditions.

Total
0
Shares
Related Posts
Read More

PDS Biotech Announces Updated Survival Data From NCI-Led Phase 2 Clinical Trial Of PDS0101-Based Triple Combination Therapy In Advanced HPV16-Positive Cancer Patients which Show 75% Survival Of ICI Naïve Patients At 36 Months

75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months12-month survival rate in ICI resistant patients is 72%Median OS

PDSB